Swedbank AB Buys 3,000 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Swedbank AB increased its stake in Medpace Holdings by 4.4%, now owning 71,000 shares valued at about $22.3 million after purchasing 3,000 additional shares.
• Insider transactions revealed significant stock sales, with General Counsel Stephen P. Ewald and CEO August J. Troendle selling 3,000 and 48,487 shares respectively, leading to a total of $74.1 million in shares sold in the last quarter.
• Analysts have varied opinions on Medpace, with UBS downgrading the stock to a "sell" rating while others set new price targets, ranging from $305 to $510, indicating mixed sentiment on future performance.

Swedbank AB increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 4.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 71,000 shares of the company's stock after buying an additional 3,000 shares during the quarter. Swedbank AB owned about 0.25% of Medpace worth $22,284,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in MEDP. GAMMA Investing LLC lifted its position in shares of Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after purchasing an additional 83 shares during the last quarter. Inspire Investing LLC purchased a new position in Medpace in the first quarter valued at about $2,059,000. Zeno Equity Partners LLP grew its stake in Medpace by 2.6% in the first quarter. Zeno Equity Partners LLP now owns 62,304 shares of the company's stock valued at $18,983,000 after purchasing an additional 1,564 shares during the last quarter. United Services Automobile Association purchased a new position in Medpace in the first quarter valued at about $500,000. Finally, Petrus Trust Company LTA purchased a new position in Medpace in the first quarter valued at about $203,000. 77.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel owned 10,343 shares in the company, valued at $4,654,350. This trade represents a 22.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares in the company, valued at $434,803,569.35. This represents a 4.80% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on MEDP shares. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and raised their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Truist Financial boosted their price target on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. TD Cowen reaffirmed a "sell" rating and set a $366.00 target price (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Mizuho upped their target price on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Medpace currently has a consensus rating of "Reduce" and an average price target of $422.27.

Medpace Price Performance

MEDP stock opened at $498.60 on Friday. The firm has a market capitalization of $14.01 billion, a P/E ratio of 37.07, a P/E/G ratio of 3.14 and a beta of 1.44. The business's 50-day moving average is $446.89 and its two-hundred day moving average is $355.24. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the prior year, the business posted $2.75 EPS. The business's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.